23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.

A pioneer in genetic heritage services, 23andMe has seen much of its share price wiped out in the past year as it struggles ...

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...

Me (ME) forms special board committee to explore strategic alternatives, including sale, restructuring, or business ...

23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...

The struggling genetic-testing 23andMe is looking for a buyer for the virtual-care business it acquired in 2021, Business ...

At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.

Reports Q3 revenue $60.3M vs. $44.75M last yearInvest with Confidence: Follow TipRanks' Top Wall Street Analysts to uncover their success rate ...

The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) ("23andMe" or the "Company"), a leading human genetics company ...

Manhattan Associates' 2025 outlook missed estimates. The provider of supply-chain and omnichannel-commerce solutions said it expects adjusted per-share earnings of $4.45 to $4.55 on revenue of $1.06 ...